The relationship between COVID-19 Infection and new onset and prognosis of vasospastic angina: Multi-center prospective study

Relationship between COVID-19 infection and new onset and prognosis of vasospastic angina; Multi-center, prospective, observational study - The relationship between COVID-19 Infection and vasospastic angina

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042248

Enrollment

300

Registered

2020-11-11

Start date

2020-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 infection and vasospastic angina

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Before the COVID-19 epidemic: -2020 / 1/31 During the COVID-19 epidemic: 2020/3 / 1-20 21/3/31 COVID-19 IgG antibody will be collected from patients undergoing outpatient treatment who had first symptom of vasospastic angina during the above period.

Exclusion criteria

Exclusion criteria: Nothing in particular

Design outcomes

Primary

Measure	Time frame
We investigate the rereshionship between the presence and absence of antibody (IgG )of COVID-19 and the following endpoints. Primary endpoints; We will compare the prevalence of COVID-19 antibody in patients with vasospasitic angina that developed before and after the COVID-19 infection epidemic.	—

Secondary

Measure	Time frame
Relationship between the presence or absence of new coronavirus antibody and 5 year cardiovascular events from registration. All cause death Cardiovascular death Myocardial infarction cerebral infarction Coronary artery revascularization Hospitalization for heart failure Revascularization for peripheral arterial disease Arrhythmia attacks requiring change of treatment Deep vein thrombosis, pulmonary embolism	—

Measure

Time frame

Relationship between the presence or absence of new coronavirus antibody and 5 year cardiovascular events from registration. All cause death Cardiovascular death Myocardial infarction cerebral infarction Coronary artery revascularization Hospitalization for heart failure Revascularization for peripheral arterial disease Arrhythmia attacks requiring change of treatment Deep vein thrombosis, pulmonary embolism

—

Countries

Japan

Contacts

Public ContactJin Kirigaya

Yokohama City University Medical Center Advanced Care and Emergency Center

kirigaya@yokohama-cu.ac.jp045-261-5656

Outcome results